SignaBlok to Present Positive Preclinical Data on TREM-1 Inhibitor at 2025 AACR Annual Meeting
March 19, 2025 — SignaBlok, Inc. to unveil groundbreaking preclinical data on macrophage-restricted TREM-1 inhibitor at 2025 AACR Annual Meeting. Exciting advancements in pancreatic cancer treatment with potential implications for other hard-to-treat tumors. Learn more about SignaBlok's innovative approach to inflammation-associated diseases.